| 引用本文:张建国，朱正炎，马军力，王礼.血脂康对介入术后冠心病合并高血脂患者预后的影响[J].世界中医药,2017,(07):. |
|
| 血脂康对介入术后冠心病合并高血脂患者预后的影响 |
| Effect of Xuezhikang on the Prognosis of Patients with Coronary Heart Disease Complicated with Hyperlipidemia after Interventional Therapy |
| 投稿时间：2017-05-05 |
| DOI：10.3969/j.issn.1673-7202.2017.07.029 |
| 中文关键词: 血脂康 冠心病 高脂血症 心功能 预后 血浆FIB |
| English Keywords:Xuezhikang Coronary disease Hyperlipidemia Cardiac function Prognosis FIB |
| 基金项目:北京市教育局科研项目(2013WJ009) |
|
| 摘要点击次数: 1015 |
| 全文下载次数: 764 |
| 中文摘要: |
| 目的:观察血脂康治疗冠心病介入术后合并高血脂患者心功能预后,并观察其对血脂和血浆FIB水平的影响。方法:选取2015—2016年在顺义区医院诊治的冠心病介入治疗术后合并高脂血症患者80例。随机分为对照组和观察组,每组40例。2组患者均予一般基础治疗,对照组予阿托伐他汀钙治疗,观察组在对照组基础上加以服用血脂康治疗,均治疗4周。治疗前后分别检测血脂、血浆FIB、PAI-1、t-PA水平,并于治疗前后及随访3个月后进行心功能评定。结果:治疗后,1)2组患者TG、TCHO、HDL-C、LDL-C均较治疗前减低(P<0.05),且观察组各项指标的改善程度明显优于对照组(P<0.05);2)2组的血浆Fib、PAI-1治疗后均降低,t-PA值增高(P<0.05),且观察组明显优于对照组(P<0.05);3)治疗后2组患者心功能都得到明显改善,观察组优于对照组(P<0.05),且3个月随访后其各项指标均优于对照组(P<0.05)。结论:血脂康可以降低冠心病合并高脂血症患者的血脂水平,改善其血液凝聚度,并可明显提高其心功能预后水平。 |
| English Summary: |
| To observe the effect of Xuezhikang on cardiac function in patients with coronary disease after percutaneous coronary intervention,and to observe the effect of Xuezhikang on blood lipid and plasma FIB level.Methods:Collect 80 patients with coronary disease after percutaneous coronary intervention in our hospital from 2015 to 2016 were randomly selected.The patients were divided into control group and observation group,40 cases in each group.Two groups of patients were treated with basic treatment,the control group was given atorvastatin calcium treatment,the treatment group in the control group on the basis of taking Xuezhikang treatment,were treated for 4 weeks.The levels of blood lipid,plasma Fib,PAI-1 and t-PA were detected before and after treatment,and the cardiac function was evaluated before and after treatment and 3 months after the treatment.Results:After treatment,two patients;1)TG,TCHO,HDL-C and LDL-C were lower than those before treatment(P<0.05),the degree of improvement and the index of the treatment group was significantly better than the control group(P<0.05);2)two groups of plasma Fib and PAI-1 after treatment were decreased,t-PA value increased(P<0.05),and the treatment group was significantly better than the control group(P<0.05);3)the two groups after treatment in patients with heart function were improved,the treatment group than the control group(P<0.05),and 3 months after the indicators were better than the control group(P<0.05).Conclusion:Xuezhikang can reduce blood lipid level of hyperlipidemia patients with coronary disease,improve the blood coagulation,and can significantly improve the prognosis of cardiac function level. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
|
|
|
